WallStreetZenWallStreetZen

NASDAQ: TCRT
Alaunos Therapeutics Revenue

OverviewEarningsRevenue
DividendOwnership
Alaunos Therapeutics revenue was $4.00k for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q2 2025) ending on Jun 30, 2025 was $0.0, down N/A from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, TCRT annual revenue was $10.0k, with 100% growth year-over-year.

TCRT past revenue growth

How has TCRT's revenue growth performed historically?

Company
-20%
Industry
148.03%
Market
17.03%
TCRT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
TCRT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

TCRT revenue history

Current Revenue
$4.0k
Current Earnings
-$4.0M
Current Profit Margin
-99,825%

Be the first to know when TCRT announces revenue.

TCRT Revenue History By Year

TCRT Yearly RevenueTCRT RevenueTCRT ChangeTCRT Revenue Growth
2024-12-31$10.00k$5.00k+100.00%
2023-12-31$5.00k-$2.92M-99.83%
2022-12-31$2.92M$2.52M+634.17%
2021-12-31$398.00kN/AN/A
2020-12-31$0.00N/AN/A
2019-12-31$0.00-$146.00k-100.00%
2018-12-31$146.00k-$6.24M-97.71%
2017-12-31$6.39M-$472.00k-6.88%
2016-12-31$6.86M$2.53M+58.38%
2015-12-31$4.33M$2.96M+215.51%
2014-12-31$1.37M$573.00k+71.63%
2013-12-31$800.00k$0.000.00%
2012-12-31$800.00k$133.00k+19.94%
2011-12-31$667.00kN/AN/A
2010-12-31$0.00N/AN/A
2009-12-31$0.00N/AN/A
2008-12-31$0.00N/AN/A
2007-12-31$0.00N/AN/A
2006-12-31$0.00N/AN/A
2005-12-31$0.00N/AN/A
2004-12-31$0.00N/AN/A

1 of 2

Alaunos Therapeutics Revenue FAQ

What was TCRT's revenue last quarter?

Alaunos Therapeutics (NASDAQ: TCRT) reported Q2 2025 revenue of $0.00 up 100% year over year. In the same quarter last year, Alaunos Therapeutics's revenue was $4.00 thousand.

What was Alaunos Therapeutics's revenue in 2024?

Alaunos Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $10.00 thousand, a 100% increase year over year.

How much does Alaunos Therapeutics make in a day?

Based on Alaunos Therapeutics annual revenue for the past five years, TCRT makes an average of $1,827.40 per day.

What was Alaunos Therapeutics's annual revenue growth in the past year?

As of Q3 2025, Alaunos Therapeutics's revenue has grown -20% year over year. This is 168.03 percentage points lower than the US Biotechnology industry revenue growth rate of 148.03%. Alaunos Therapeutics's revenue in the past year totaled $4.00 thousand.

How much does Alaunos Therapeutics make in a year?

Alaunos Therapeutics's revenue by year for the past five years is:
  • Alaunos Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $10.00 thousand, a 100% increase year over year.
  • Alaunos Therapeutics's annual revenue for Dec 31, 2023 was $5.00 thousand, a 99.83% decrease from 2022.
  • Alaunos Therapeutics's annual revenue for 2022 was $2.92 million, a 634.17% increase from 2021.
  • Alaunos Therapeutics's annual revenue for 2021 was $398.00 thousand, a Infinity% increase from 2020.
  • Alaunos Therapeutics's annual revenue for 2020 was $0.00, a N/A decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.